[go: up one dir, main page]

MA39734A - Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation - Google Patents

Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation

Info

Publication number
MA39734A
MA39734A MA039734A MA39734A MA39734A MA 39734 A MA39734 A MA 39734A MA 039734 A MA039734 A MA 039734A MA 39734 A MA39734 A MA 39734A MA 39734 A MA39734 A MA 39734A
Authority
MA
Morocco
Prior art keywords
therapeutic
manufacturing
therapeutic agent
nanoparticles containing
use methods
Prior art date
Application number
MA039734A
Other languages
English (en)
Other versions
MA39734B1 (fr
Inventor
Shubha Bagrodia
Jennifer LAFONTAINE
Zach Lovatt
Eyoung Shin
Young Ho Song
Greg Troiano
Hong Wang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA39734A publication Critical patent/MA39734A/fr
Publication of MA39734B1 publication Critical patent/MA39734B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne, d'une manière générale, des nanoparticules comprenant un acide sensiblement hydrophobe et un agent thérapeutique (1-(4-{[4-(diméthylamino)pipéridin-1-yl]carbonyl}phényl)-3-[4- (4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phényl]urée), ou des sels pharmaceutiquement acceptables de celui-ci, et un polymère. D'autres aspects concernent des procédés de fabrication et d'utilisation de telles nanoparticules.
MA39734A 2014-03-14 2015-03-13 Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation MA39734B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461953628P 2014-03-14 2014-03-14
PCT/US2015/020343 WO2015138835A1 (fr) 2014-03-14 2015-03-13 Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation

Publications (2)

Publication Number Publication Date
MA39734A true MA39734A (fr) 2017-01-18
MA39734B1 MA39734B1 (fr) 2019-07-31

Family

ID=52780047

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39734A MA39734B1 (fr) 2014-03-14 2015-03-13 Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation

Country Status (42)

Country Link
US (4) US9895378B2 (fr)
EP (2) EP3116547B1 (fr)
JP (2) JP6348616B2 (fr)
KR (1) KR20160126084A (fr)
CN (1) CN106163503B (fr)
AP (1) AP2016009494A0 (fr)
AR (1) AR099756A1 (fr)
AU (2) AU2015229210B2 (fr)
BR (1) BR112016021130A2 (fr)
CA (1) CA2942859A1 (fr)
CL (1) CL2016002308A1 (fr)
CR (1) CR20160477A (fr)
CU (1) CU24488B1 (fr)
CY (1) CY1122078T1 (fr)
DK (2) DK3116547T3 (fr)
DO (1) DOP2016000244A (fr)
EA (1) EA032234B1 (fr)
EC (1) ECSP16081557A (fr)
ES (2) ES2737692T3 (fr)
GE (1) GEP20207083B (fr)
HR (1) HRP20191187T1 (fr)
HU (1) HUE043964T2 (fr)
IL (1) IL247346B (fr)
LT (1) LT3116547T (fr)
MA (1) MA39734B1 (fr)
ME (1) ME03435B (fr)
MX (1) MX378984B (fr)
MY (1) MY178189A (fr)
NI (1) NI201600138A (fr)
PE (1) PE20170312A1 (fr)
PH (1) PH12016501794A1 (fr)
PL (1) PL3116547T3 (fr)
PT (1) PT3116547T (fr)
RS (1) RS59035B9 (fr)
SA (1) SA516371814B1 (fr)
SG (1) SG11201607645TA (fr)
SI (1) SI3116547T1 (fr)
SV (1) SV2016005277A (fr)
TW (2) TWI636798B (fr)
UA (1) UA121967C2 (fr)
WO (1) WO2015138835A1 (fr)
ZA (1) ZA201606646B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
DK3104838T3 (da) * 2014-02-13 2020-02-24 Pfizer Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf
RU2771104C2 (ru) 2014-05-14 2022-04-26 Таргиммьюн Терапьютикс Аг Улучшенные полиэтилениминовые полиэтиленгликолевые векторы
US10172942B2 (en) 2014-12-17 2019-01-08 Pfizer Inc. Formulations of a PI3K/mTor-inhibitor for intravenous administration
WO2017062920A1 (fr) * 2015-10-07 2017-04-13 Chopra Sunandini Nanoparticules à libération de médicament déclenchée par un changement de ph
HK1256886A1 (zh) * 2015-10-30 2019-10-04 Pfizer Inc. 包含治疗剂的治疗性纳米颗粒及其制备和使用方法
EP3432866A1 (fr) * 2016-03-25 2019-01-30 Pfizer Inc Formulations stables pour particules thérapeutiques de lyophilisation
US10369230B2 (en) 2017-04-06 2019-08-06 National Guard Health Affairs Sustained release of a therapeutic agent from PLA-PEG-PLA nanoparticles for cancer therapy
ES2895370T3 (es) 2017-08-25 2022-02-21 Pfizer Formulación farmacéutica acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea
NZ805649A (en) * 2018-06-07 2024-11-29 Pfizer Aqueous formulation comprising 1-(4-{ [4-(dimethylamino)piperidin-1-yl]carbonyl} phenyl)-3- [4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CN111286204B (zh) * 2020-03-12 2021-08-20 复旦大学 一种遇含水溶剂快速溶解或分散的高分子复合物及其制备方法和应用
RU2751699C1 (ru) * 2020-07-17 2021-07-15 Федеральное казённое учреждение здравоохранения "Ставропольский научно-исследовательский противочумный институт" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения наночастиц хитозана с включенным ципрофлоксацином
AU2021357354A1 (en) 2020-10-08 2023-04-20 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
TW202320795A (zh) 2021-07-26 2023-06-01 美商凱爾科迪股份有限公司 使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法
WO2023079142A2 (fr) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Conjugués linéaires ciblés comprenant du polyéthylèneimine et du polyéthylène glycol et polyplexes comprenant ceux-ci
WO2023150246A1 (fr) * 2022-02-04 2023-08-10 Virginia Commonwealth University Formulations à libération prolongée et leurs procédés d'utilisation
WO2024100046A1 (fr) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Conjugués linéaires ciblés comprenant du polyéthylèneimine et du polyéthylène glycol et polyplexes comprenant ceux-ci
KR20250106292A (ko) 2022-11-07 2025-07-09 타르그이뮨 테라퓨틱스 아게 폴리에틸렌이민 및 폴리에틸렌 글리콜을 포함하는 psma 표적화 선형 컨쥬게이트 및 이들을 포함하는 다중복합체
IL320618A (en) 2022-11-07 2025-07-01 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
US11833224B1 (en) 2023-02-08 2023-12-05 Leuvian Llc Lyoprotectant compositions and uses thereof
WO2025128712A1 (fr) 2023-12-12 2025-06-19 Celcuity Inc. Traitement de maladies oculaires à l'aide de 1-(4-{[4-(diméthylamino)pipéridin-1-yl]carbonyl)phényl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phényl]urée
WO2025238236A1 (fr) 2024-05-16 2025-11-20 Targimmune Therapeutics Ag Polyplexes d'acides nucléiques et conjugués ciblés comprenant de la polyéthylèneimine et du polyéthylène glycol

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE113468T1 (de) 1987-07-29 1994-11-15 Liposome Co Inc Verfahren zur trennung von teilchen nach grösse.
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US5563122A (en) 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
EP0805678B1 (fr) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Nanoparticules a modification de surface et leurs procedes de fabrication et d'utilisation
DK0814778T3 (da) 1995-03-10 2001-09-17 Roche Diagnostics Gmbh Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
JP2942508B2 (ja) 1997-01-14 1999-08-30 順也 藤森 温度感受性徐放性基剤及び温度感受性徐放性システム
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6254890B1 (en) 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
CN1321092A (zh) 1998-06-30 2001-11-07 安姆根有限公司 用于生物活性剂的延缓给药的热敏生物可降解水凝胶
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
KR100274842B1 (ko) 1998-10-01 2001-03-02 김효근 미립구를 이용한 레티노익산의 서방형 약물방출 시스템
DE19856432A1 (de) 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
AU6132700A (en) 1999-09-30 2001-04-05 Chienna B.V. Polymers loaded with bioactive agents
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US20050037086A1 (en) 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US6890946B2 (en) 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
KR100418916B1 (ko) 2000-11-28 2004-02-14 한국과학기술원 생분해성 고분자와 항암제의 접합체를 이용한 서방형미셀제제의 제조방법
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
ES2292634T3 (es) 2000-12-21 2008-03-16 Alrise Biosystems Gmbh Procedimiento de transicion de fase inducida para la produccion de microparticulas que contienen agentes hidrofilos activos.
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
ATE374603T1 (de) 2000-12-27 2007-10-15 Ares Trading Sa Amphiphile lipid-nanopartikel zur peptid- und/oder proteininkorporation
CA2436408A1 (fr) 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Ligands de la psma modifies et utilisation de ces derniers
WO2002080846A2 (fr) 2001-04-03 2002-10-17 Kosan Biosciences, Inc. Derives d'epothilone : procedes de fabrication et methodes d'utilisation associes
EP1492554B1 (fr) 2001-06-21 2019-08-21 Althea Technologies, Inc. Particules de proteine spheriques
US7498045B2 (en) 2001-08-31 2009-03-03 Thomas M. S. Chang Biodegradable polymeric nanocapsules and uses thereof
WO2003055469A1 (fr) 2001-12-21 2003-07-10 Celator Technologies Inc. Vecteur ameliore a base de polymere et de lipide
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
CN100518828C (zh) 2001-10-10 2009-07-29 皮埃尔法布雷医药公司 缓释可生物降解微球体及其制备方法
WO2003032906A2 (fr) 2001-10-15 2003-04-24 Crititech, Inc. Compositions et methodes d'administration de medicaments faiblement hydrosolubles et methodes de traitement
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
WO2003060523A1 (fr) 2002-01-10 2003-07-24 Johns Hopkins University Agents d'imagerie et procedes d'imagerie de naaladase et psma
WO2003086369A2 (fr) 2002-04-05 2003-10-23 Valorisation-Recherche, Societe En Commandite Nanospheres biodegradables polymeriques discretes et leurs utilisations
US20030232887A1 (en) 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds
AU2003228666A1 (en) 2002-04-23 2003-11-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
JP2003342168A (ja) 2002-05-24 2003-12-03 Nano Career Kk 注射用薬物含有ポリマーミセル製剤の製造方法
JP4448441B2 (ja) 2002-06-05 2010-04-07 ユニヴァーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 眼科用医薬のデリバリーシステム
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
US7879351B2 (en) 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
EP1569620A4 (fr) 2002-10-30 2006-03-22 Spherics Inc Agents bioactifs nanoparticulaires
AU2003293195A1 (en) 2002-12-23 2004-07-29 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
US6841547B2 (en) 2003-02-28 2005-01-11 Albert Einstein College Of Medicine Of Yeshevia University Method for decreasing low density lipoprotein
US20040185170A1 (en) 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
EP2186510B1 (fr) 2003-03-26 2013-07-10 Egalet Ltd. Compositions matricielles pour l'administration contrôlée de médicaments
WO2004084871A1 (fr) 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Nanoparticules intraveineuses pour cibler une administration de medicaments et pour une liberation de medicaments prolongee
CA2520475C (fr) 2003-04-03 2012-10-09 Jessie L.-S. Au Particules a charge medicamenteuse ciblant les tumeurs
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
BRPI0412211A (pt) 2003-07-23 2006-08-22 Pr Pharmaceuticals Inc composições de liberação controlada
BRPI0414043A (pt) 2003-09-02 2006-10-24 Novartis Ag tratamento de cáncer com epotilonas
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
US7846412B2 (en) 2003-12-22 2010-12-07 Emory University Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US20050266067A1 (en) 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
WO2006002365A2 (fr) 2004-06-24 2006-01-05 Angiotech International Ag Microparticules fortement chargees en agent bioactif
EP1768692B8 (fr) 2004-07-01 2015-06-17 Yale University Materiaux polymères chargés de médicaments et ciblés à haute densité
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
JP2006131577A (ja) 2004-11-09 2006-05-25 Ltt Bio-Pharma Co Ltd 異なる粒子径を有する薬物封入ナノ粒子の作製方法および当該方法で得られたナノ粒子
BRPI0519739A2 (pt) 2004-12-30 2009-03-10 Cinv Ag combinaÇço compreendendo um agente fornecendo um sinal, um material de implante e uma droga
WO2006093991A1 (fr) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Composes se liant a l'antigene membranaire specifique de la prostate (psma) et utilisations associees
WO2006107957A2 (fr) 2005-04-04 2006-10-12 Sinexus, Inc. Dispositifs et procedes de traitement des affections sinus paranasaux
JP2006321763A (ja) 2005-05-20 2006-11-30 Hosokawa Funtai Gijutsu Kenkyusho:Kk 生体適合性ナノ粒子及びその製造方法
AU2006282042B2 (en) 2005-06-17 2011-12-22 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials
WO2007008994A2 (fr) 2005-07-11 2007-01-18 Wyeth Inhibiteurs de glutamate aggrecanase
WO2007019232A2 (fr) 2005-08-03 2007-02-15 Immunogen, Inc. Formulations d'immunoconjugué
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US8765181B2 (en) 2005-09-09 2014-07-01 Beijing Diacrid Medical Technology Co., Ltd Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids
US20090022806A1 (en) 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
JP2009508936A (ja) 2005-09-20 2009-03-05 イッサム リサーチ ディベロップメント カンパニー 活性物質の標的化送達用ナノ粒子
CA2631714C (fr) 2005-12-02 2014-09-16 Novartis Ag Nanoparticules destinees a etre utilisees dans des compositions immunogenes
JP5131971B2 (ja) 2005-12-26 2013-01-30 株式会社Ｌｔｔバイオファーマ 水溶性非ペプチド性低分子薬物含有ナノ粒子
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
JP2009528294A (ja) 2006-02-23 2009-08-06 エリモス・ファーマスーティカルズ・エルエルシー インフルエンザウイルス感染症の治療方法
DE102006013531A1 (de) 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
WO2008105773A2 (fr) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology Système pour l'administration ciblée d'agents thérapeutiques
JP5630998B2 (ja) * 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
ES2401299T5 (es) 2006-07-26 2016-04-06 Sandoz Ag Formulaciones de caspofungina
JP2010511595A (ja) 2006-07-31 2010-04-15 ニューロシステック コーポレイション 遊離塩基ガシクリジンナノ粒子
EP2050449A4 (fr) 2006-07-31 2010-10-06 Senju Pharma Co Préparation liquide aqueuse contenant un amide
US20100144845A1 (en) 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20080057102A1 (en) 2006-08-21 2008-03-06 Wouter Roorda Methods of manufacturing medical devices for controlled drug release
CA2663558C (fr) 2006-09-26 2013-05-28 Samyang Corporation Nanoparticule submicronique de derives de camptothecine faiblement solubles dans l'eau et son procede de preparation
PT3699162T (pt) 2006-11-08 2022-10-11 Molecular Insight Pharm Inc Heterodímeros de ácido glutâmico
WO2008147456A2 (fr) 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Systèmes d'administration de médicaments en utilisant des fragments fc
CN1957911A (zh) 2006-12-01 2007-05-09 济南康泉医药科技有限公司 一种抗实体肿瘤缓释剂
CN1969818A (zh) 2006-12-12 2007-05-30 济南帅华医药科技有限公司 一种含埃坡霉素衍生物的抗癌缓释注射剂
CN101396340A (zh) 2006-12-12 2009-04-01 济南帅华医药科技有限公司 一种含埃坡霉素衍生物的抗癌缓释注射剂
CN1969816A (zh) 2006-12-12 2007-05-30 济南帅华医药科技有限公司 一种含埃坡霉素的抗癌缓释剂
CN1961864A (zh) 2006-12-12 2007-05-16 济南帅华医药科技有限公司 一种抗癌的组合物
CN101396342A (zh) 2006-12-12 2009-04-01 济南帅华医药科技有限公司 含埃坡霉素衍生物的抗癌缓释注射剂
CN101433520A (zh) 2006-12-12 2009-05-20 济南帅华医药科技有限公司 含埃坡霉素的抗癌缓释剂
WO2008091465A2 (fr) 2006-12-21 2008-07-31 Wayne State University Peg et ligands de ciblage sur une surface de nanoparticule
CA3201293A1 (fr) 2007-03-07 2008-09-12 Abraxis Bioscience, Llc Nanoparticule comprenant de la rapamycine et de l'albumine utilisee comme agent anticancereux
CN101053553B (zh) 2007-03-16 2011-04-20 吉林大学 一种生物可降解氟尿嘧啶聚酯载药纳米球及其制备方法
WO2008124639A2 (fr) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Fractions de ciblage de poly (acide aminé)
WO2008124634A1 (fr) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Micelles inverses encapsulées par un polymère
US20100129456A1 (en) 2007-05-14 2010-05-27 Ltt Bio-Pharma Co., Ltd. Sustained-release nanoparticle containing low-molecular-weight drug with negatively charged group
CA2990445C (fr) 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Melange thermocinetique pour des applications pharmaceutiques
US20090061009A1 (en) 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
ES2376175T3 (es) 2007-09-28 2012-03-09 Bind Biosciences, Inc. Direccionamiento a células de c�?ncer usando nanopart�?culas.
US20090306120A1 (en) 2007-10-23 2009-12-10 Florencia Lim Terpolymers containing lactide and glycolide
US8974814B2 (en) 2007-11-12 2015-03-10 California Institute Of Technology Layered drug delivery polymer monofilament fibers
US9422234B2 (en) 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
WO2009084801A1 (fr) 2007-12-31 2009-07-09 Samyang Corporation Composition micellaire de copolymère à blocs amphiphiles contenant du taxane et son procédé de fabrication
EP2106806A1 (fr) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticules pour la livraison ciblée d'agents actifs vers les poumons
CN102215830A (zh) * 2008-05-06 2011-10-12 葛兰素集团有限公司 生物活性剂的囊封方法
US20090312402A1 (en) 2008-05-20 2009-12-17 Contag Christopher H Encapsulated nanoparticles for drug delivery
EP2300483A1 (fr) 2008-05-23 2011-03-30 Wyeth LLC Composés de triazine formant des inhibiteurs de pi3-kinase et mtor
CN102099016A (zh) * 2008-06-16 2011-06-15 佰恩德生物科学股份有限公司 载药的聚合物纳米微粒及其制备和使用方法
WO2010005740A2 (fr) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Procédés pour la préparation de copolymères diblocs fonctionnalisés avec un agent de ciblage destinés à être utilisés dans la fabrication de nanoparticules ciblées thérapeutiques
WO2010005726A2 (fr) 2008-06-16 2010-01-14 Bind Biosciences Inc. Nanoparticules polymères thérapeutiques avec inhibiteurs de mtor et procédés de fabrication et d’utilisation associés
JP2012501965A (ja) * 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
EP2309991B1 (fr) 2008-06-16 2019-03-06 Pfizer Inc Nanoparticules polymères thérapeutiques comprenant des alcaloïdes vinca et procédés de fabrication et d utilisation associés
BRPI0915825A2 (pt) 2008-07-08 2015-11-03 Abbott Lab proteínas de ligação à prostaglandina e2 usos das mesmas
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
US20110125090A1 (en) 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
EP2379064B1 (fr) 2008-12-15 2020-02-26 Pfizer Inc. Longues nanoparticules circulantes pour la libération prolongée d'agents thérapeutiques
EP2413901A4 (fr) 2009-03-30 2015-05-06 Cerulean Pharma Inc Conjugués polymère-agent, particules, compositions et procédés d'utilisation apparentés
WO2010114770A1 (fr) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-agent, particules, compositions et procédés d'utilisation apparentés
WO2010114768A1 (fr) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-épothilone, particules, compositions et procédés d'utilisation apparentés
EP3167875A1 (fr) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Réduction d'agrégation de type paillettes dans des compositions de meloxicam nanoparticulaire
EP2499486A4 (fr) * 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc Compositions, kits, et procédés pour l'identification, l'évaluation, la prévention, et la thérapie d'un cancer
WO2011072218A2 (fr) 2009-12-11 2011-06-16 Bind Biosciences Formulations stables pour particules thérapeutiques de lyophilisation
ES2780156T3 (es) 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
EA201290497A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
WO2011084521A2 (fr) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Nanoparticules polymères thérapeutiques comportant de l'épothilone et leurs procédés de fabrication et d'utilisation
CN102740895B (zh) 2009-12-23 2016-02-24 伊利诺伊大学董事会 纳米轭合物以及纳米轭合物配制品
WO2011119995A2 (fr) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations et procédés d'utilisation
WO2012040513A1 (fr) 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Compositions et procédés d'administration de bêta-lapachone
EA201390600A1 (ru) 2010-10-22 2013-09-30 Байнд Терапьютикс, Инк. Терапевтические наночастицы с сополимерами с большим молекулярным весом
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
JP2014531456A (ja) 2011-09-22 2014-11-27 バインド セラピューティックス インコーポレイテッド 治療用ナノ粒子と癌を治療する方法
ES2946549T3 (es) 2012-01-13 2023-07-20 Xspray Pharma Ab Publ Composición farmacéutica de nilotinib
US10561733B2 (en) 2012-02-29 2020-02-18 Merck Patent Gmbh Process for producing nanoparticles laden with active ingredient
WO2014043625A1 (fr) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Nanoparticules thérapeutiques comprenant un agent thérapeutique et leurs procédés de fabrication et d'utilisation
US9877923B2 (en) 2012-09-17 2018-01-30 Pfizer Inc. Process for preparing therapeutic nanoparticles
BR112015032758A2 (pt) 2013-06-28 2017-07-25 Bind Therapeutics Inc nanopartículas poliméricas de docetaxel para o tratamento de câncer

Also Published As

Publication number Publication date
ES2737692T3 (es) 2020-01-15
US20180125854A1 (en) 2018-05-10
ZA201606646B (en) 2018-04-25
TW201834658A (zh) 2018-10-01
EP3116547A1 (fr) 2017-01-18
ME03435B (fr) 2020-01-20
CU20160135A7 (es) 2017-02-02
NI201600138A (es) 2016-10-14
US20210177857A1 (en) 2021-06-17
SG11201607645TA (en) 2016-10-28
TWI636798B (zh) 2018-10-01
CN106163503A (zh) 2016-11-23
EP3511019A1 (fr) 2019-07-17
US20180344746A1 (en) 2018-12-06
PL3116547T3 (pl) 2019-11-29
TW201620505A (zh) 2016-06-16
CL2016002308A1 (es) 2017-05-26
SV2016005277A (es) 2017-03-20
TWI693937B (zh) 2020-05-21
MX2016012009A (es) 2016-12-05
CR20160477A (es) 2017-02-24
BR112016021130A2 (pt) 2017-08-15
AR099756A1 (es) 2016-08-17
SI3116547T1 (sl) 2019-08-30
CY1122078T1 (el) 2020-11-25
MY178189A (en) 2020-10-06
PT3116547T (pt) 2019-07-25
HRP20191187T1 (hr) 2019-10-04
HUE043964T2 (hu) 2019-09-30
LT3116547T (lt) 2019-07-25
JP2018154643A (ja) 2018-10-04
IL247346B (en) 2019-05-30
DK3511019T3 (da) 2020-10-26
SA516371814B1 (ar) 2019-09-30
US20150258102A1 (en) 2015-09-17
US9895378B2 (en) 2018-02-20
MA39734B1 (fr) 2019-07-31
KR20160126084A (ko) 2016-11-01
ECSP16081557A (es) 2019-02-28
AU2019240695A1 (en) 2019-10-24
UA121967C2 (uk) 2020-08-25
ES2834927T3 (es) 2021-06-21
AU2015229210A1 (en) 2016-10-06
GEP20207083B (en) 2020-04-10
EP3116547B1 (fr) 2019-06-05
EA201691692A1 (ru) 2017-02-28
EA032234B1 (ru) 2019-04-30
CU24488B1 (es) 2020-11-30
IL247346A0 (en) 2016-11-30
US10071100B2 (en) 2018-09-11
AP2016009494A0 (en) 2016-10-31
AU2015229210B2 (en) 2019-07-04
PH12016501794A1 (en) 2016-11-07
EP3511019B1 (fr) 2020-10-14
DOP2016000244A (es) 2017-03-31
PE20170312A1 (es) 2017-03-30
DK3116547T3 (da) 2019-07-15
WO2015138835A1 (fr) 2015-09-17
RS59035B1 (sr) 2019-08-30
JP2017508803A (ja) 2017-03-30
JP6348616B2 (ja) 2018-06-27
CN106163503B (zh) 2021-02-26
MX378984B (es) 2025-03-11
CA2942859A1 (fr) 2015-09-17
RS59035B9 (sr) 2019-11-29

Similar Documents

Publication Publication Date Title
MA39734A (fr) Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
TR201905683T4 (tr) Aşındırıcı presbiyopi için oftalmik formülasyon ve yöntem.
PH12018550173A1 (en) Pyrazolopyrimidine derivatives
BR112018071216A2 (pt) inibidores de bromodomínios
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
BR112014016233B1 (pt) inibidores de bromodomínio
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
MX380798B (es) Profármacos de alvocidib que tienen una biodisponibilidad aumentada.
WO2016061232A3 (fr) Sharn multiplexés et leurs utilisations
HK1254608A1 (zh) 改良的地拉罗司制剂及其制备方法
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
CO7141410A2 (es) Compuesto heterocíclico nitrogenado
ZA201802312B (en) A group of compounds used for the treatment or prevention of hyperuricemia or gout
SG10201909209RA (en) Nucleic acid-cationic polymer compositions and methods of making and using the same
MX2014014468A (es) Compuestos triazolo como inhibidores de fosfodiesterasa 10 (pde10).
MX2018000990A (es) Composiciones para el cuidado bucal que contienen polimeros, copolimeros o polimeros reticulados de amps.
MX2014002682A (es) Modulares de la fosfodiesterasa 10 (pde 10).
BR112015018047A2 (pt) composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão
CO7151489A2 (es) Forma amorfa de un compuesto de pirimidinilciclopentano, inhibidor akt, composiciones y métodos del mismo
WO2014153459A3 (fr) Hap fluorescente : colorant de diagnostic pour noyaux vhb dans des cellules
BR112018013033A2 (pt) compostos de indolinonas e seu uso no tratamentod de doenças fibróticas
HK1232145A1 (zh) 雙功能化合物和用於降低尿酸水平的用途
EP2863897A4 (fr) Nanoparticules d'indirubine, leurs dérivés et leurs procédés de fabrication et d'utilisation
NZ705813A (en) Treatment of mild and moderate alzheimer’s disease